Trexquant Investment LP increased its stake in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 482.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 520,043 shares of the biopharmaceutical company's stock after purchasing an additional 430,697 shares during the quarter. Trexquant Investment LP owned approximately 0.09% of Royalty Pharma worth $13,266,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Cerity Partners LLC raised its stake in shares of Royalty Pharma by 11.1% in the third quarter. Cerity Partners LLC now owns 32,896 shares of the biopharmaceutical company's stock worth $931,000 after buying an additional 3,291 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Royalty Pharma by 6.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,972,201 shares of the biopharmaceutical company's stock worth $84,084,000 after acquiring an additional 174,874 shares during the period. Verition Fund Management LLC lifted its holdings in Royalty Pharma by 39.7% during the third quarter. Verition Fund Management LLC now owns 27,869 shares of the biopharmaceutical company's stock valued at $788,000 after purchasing an additional 7,919 shares in the last quarter. ArrowMark Colorado Holdings LLC purchased a new position in Royalty Pharma during the third quarter valued at approximately $2,030,000. Finally, Investment Management Corp of Ontario increased its stake in shares of Royalty Pharma by 47.5% in the third quarter. Investment Management Corp of Ontario now owns 12,733 shares of the biopharmaceutical company's stock worth $360,000 after purchasing an additional 4,100 shares in the last quarter. 54.35% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several research analysts recently weighed in on RPRX shares. Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. TD Cowen raised Royalty Pharma to a "strong-buy" rating in a research note on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $41.60.
Get Our Latest Stock Report on RPRX
Royalty Pharma Price Performance
Shares of Royalty Pharma stock traded down $0.68 during trading on Friday, reaching $31.11. 7,264,512 shares of the stock traded hands, compared to its average volume of 3,173,692. Royalty Pharma plc has a 52-week low of $24.05 and a 52-week high of $34.20. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The business has a fifty day simple moving average of $32.52 and a two-hundred day simple moving average of $28.97. The company has a market capitalization of $17.93 billion, a price-to-earnings ratio of 21.46, a P/E/G ratio of 2.31 and a beta of 0.50.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Sell-side analysts expect that Royalty Pharma plc will post 4.49 EPS for the current year.
Royalty Pharma Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were paid a dividend of $0.22 per share. This is an increase from Royalty Pharma's previous quarterly dividend of $0.21. The ex-dividend date was Friday, February 21st. This represents a $0.88 dividend on an annualized basis and a yield of 2.83%. Royalty Pharma's dividend payout ratio is presently 60.69%.
About Royalty Pharma
(
Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Featured Stories
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
